©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2025; 16(6): 104665
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.104665
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.104665
Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy
Gui-Zhi Li, Hong Zhou, Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Jia-Yin Liu, Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Co-first authors: Gui-Zhi Li and Jia-Yin Liu.
Author contributions: Li GZ and Liu JY contributed equally; Li GZ contributed to conceptualization, writing - original draft; Liu JY contributed to writing - review, resources, analysis; Zhou H modified the original manuscript; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Hong Zhou, MD, Chief Physician, Professor, Department of Endo
Received: December 28, 2024
Revised: March 24, 2025
Accepted: May 7, 2025
Published online: June 15, 2025
Processing time: 168 Days and 9.8 Hours
Revised: March 24, 2025
Accepted: May 7, 2025
Published online: June 15, 2025
Processing time: 168 Days and 9.8 Hours
Core Tip
Core Tip: Ferroptosis, a form of iron-dependent programmed cell death, plays a key role in the development of diabetic cardiomyopathy (DCM), contributing to oxidative stress, inflammation, and myocardial damage. Inhibiting ferroptosis can potentially alleviate DCM and prevent its progression to heart failure. This emerging pathway offers a promising therapeutic target for DCM, providing new hope for the management of DCM.